The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain

eLife

Volumn 5, Issue JANUARY2016, 2016, Pages

  Mysling, Simon ^a,b,c   Kristensen, Kristian Kølby ^a,b   Larsson, Mikael ^d   Beigneux, Anne P ^d   Gårdsvoll, Henrik ^a,b   Loren, Fong G ^d   Bensadouen, André ^e   Jørgensen, Thomas J D ^c   Young, Stephen G ^d,f   Ploug, Michael ^a,b  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Cornell University ^*  (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTEROPEPTIDASE; ESTERASE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED HIGH DENSITY LIPOPROTEIN BINDING PROTEIN 1; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; UNCLASSIFIED DRUG; GPIHBP1 PROTEIN, HUMAN; LIPOPROTEIN RECEPTOR; PROTEIN BINDING;

ARTICLE; CATALYSIS; CEREBROVASCULAR ACCIDENT; ENZYME ACTIVITY; HEART INFARCTION; HUMAN; MISSENSE MUTATION; NONHUMAN; PANCREATITIS; PROTEIN UNFOLDING; ANIMAL; CELL LINE; CHEMISTRY; ENZYME ACTIVE SITE; ENZYME STABILITY; KINETICS; MASS SPECTROMETRY; METABOLISM; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FOLDING; SURFACE PLASMON RESONANCE;

ANIMALS; CATALYTIC DOMAIN; CELL LINE; ENZYME STABILITY; HUMANS; KINETICS; LIPOPROTEIN LIPASE; MASS SPECTROMETRY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAINS; PROTEIN FOLDING; RECEPTORS, LIPOPROTEIN; SURFACE PLASMON RESONANCE;

EID: 84958559658     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.12095.001     Document Type: Article

References (58)

1. Beigneux AP, Davies BSJ, Gin P, Weinstein MM, Farber E, Qiao X, Peale F, Bunting S, Walzem RL, Wong JS, Blaner WS, Ding Z-M, Melford K, Wongsiriroj N, Shu X, de Sauvage F, Ryan RO, Fong LG, Bensadoun A, Young SG, Weinstein MM, Farber E, Qiao X, Peale F. 2007. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metabolism 5: 279-291. doi: 10. 1016/j. cmet. 2007. 02. 002.
2. Beigneux AP, Franssen R, Bensadoun A, Gin P, Melford K, Peter J, Walzem RL, Weinstein MM, Davies BSJ, Kuivenhoven JA, Kastelein JJP, Fong LG, Dallinga-Thie GM, Young SG. 2009. Chylomicronemia with a mutant GPIHBP1 (q115P) that cannot bind lipoprotein lipase. Arteriosclerosis, Thrombosis, and Vascular Biology 29: 956-962. doi: 10. 1161/ATVBAHA. 109. 186577.
3. Beigneux AP, Davies BSJ, Tat S, Chen J, Gin P, Voss CV, Weinstein MM, Bensadoun A, Pullinger CR, Fong LG, Young SG. 2011. Assessing the role of the glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (gPIHBP1) three-finger domain in binding lipoprotein lipase. Journal of Biological Chemistry 286: 19735-19743. doi: 10. 1074/jbc. M111. 242024.
4. Beigneux AP, Fong LG, Bensadoun A, Davies BSJ, Oberer M, Gardsvoll H, Ploug M, Young SG, Bensadoun A, Davies BS, Oberer M, Gårdsvoll H, Ploug M. 2015. GPIHBP1 missense mutations often cause multimerization of GPIHBP1 and thereby prevent lipoprotein lipase binding. Circulation Research 116: 624-632. doi: 10. 1161/CIRCRESAHA. 116. 305085.
5. Bensadoun A, Mottler CD, Pelletier C, Wu D, Seo JJ, Leung CS, Adeyo O, Goulbourne CN, Gin P, Fong LG, Young SG, Beigneux AP, Adeyo O. 2014. A new monoclonal antibody, 4-1a, that binds to the amino terminus of human lipoprotein lipase. Biochimica Et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 1841: 970-976. doi: 10. 1016/j. bbalip. 2014. 03. 008.
6. Brahm AJ, Hegele RA. 2015. Chylomicronaemia-current diagnosis and future therapies. Nature Reviews Endocrinology 11: 352-362. doi: 10. 1038/nrendo. 2015. 26.
7. Brown WV, Goldberg IJ, Young SG. 2015. JCL roundtable: hypertriglyceridemia due to defects in lipoprotein lipase function. Journal of Clinical Lipidology 9: 274-280. doi: 10. 1016/j. jacl. 2015. 03. 009.
8. Buonuomo PS, Bartuli A, Rabacchi C, Bertolini S, Calandra S. 2015. A 3-day-old neonate with severe hypertriglyceridemia from novel mutations of the GPIHBP1 gene. Journal of Clinical Lipidology 9: 265-270. doi: 10. 1016/j. jacl. 2014. 10. 003.
9. Chang SF, Reich B, Brunzell JD, Will H. 1998. Detailed characterization of the binding site of the lipoprotein lipase-specific monoclonal antibody 5D2. Journal of Lipid Research 39: 2350-2359.
10. Cheng CF, Bensadoun A, Bersot T, Hsu JS, Melford KH. 1985. Purification and characterization of human lipoprotein lipase and hepatic triglyceride lipase. reactivity with monoclonal antibodies to hepatic triglyceride lipase. The Journal of Biological Chemistry 260: 10720-10727.
11. Davies BSJ, Beigneux AP, Barnes RH, Tu Y, Gin P, Weinstein MM, Nobumori C, Nyré n R, Goldberg I, Olivecrona G, Bensadoun A, Young SG, Fong LG, Gin P, Weinstein MM, Nobumori C. 2010. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metabolism 12: 42-52. doi: 10. 1016/j. cmet. 2010. 04. 016.
12. Dosztanyi Z, Csizmok V, Tompa P, Simon I. 2005. IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 21: 3433-3434.
13. Foubert L, Bruin T, Gennes JLD, Ehrenborg E, Furioli J, Kastelein J, Benlian P, Hayden M. 1997. A single Ser259Arg mutation in the gene for lipoprotein lipase causes chylomicronemia in moroccans of berber ancestry. Human Mutation 10: 179-185. doi: 10. 1002/(SICI)1098-1004(1997)10: 3<179:: AID-HUMU1>3. 0. CO; 2-E.
14. Gin P, Yin L, Davies BSJ, Weinstein MM, Ryan RO, Bensadoun A, Fong LG, Young SG, Beigneux AP. 2008. The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons. Journal of Biological Chemistry 283: 29554-29562. doi: 10. 1074/jbc. M802579200.
15. Gin P, Goulbourne CN, Adeyo O, Beigneux AP, Davies BSJ, Tat S, Voss CV, Bensadoun A, Fong LG, Young SG. 2012. Chylomicronemia mutations yield new insights into interactions between lipoprotein lipase and GPIHBP1. Human Molecular Genetics 21: 2961-2972. doi: 10. 1093/hmg/dds127.
16. Ginzinger DG, Lewis ME, Ma Y, Jones BR, Liu G, Jones SD. 1996. A mutation in the lipoprotein lipase gene is the molecular basis of chylomicronemia in a colony of domestic cats. Journal of Clinical Investigation 97: 1257-1266. doi: 10. 1172/JCI118541.
17. Glaser RW, Schö nherr R, Heinemann SH. 2014. Fixed charges in the gel matrix of sensor chips and dissociation in diffusion gradients influence the detection of fast protein-protein interactions. Biosystems 116: 27-35. doi: 10. 1016/j. biosystems. 2013. 09. 009.
18. Goulbourne CN, Gin P, Tatar A, Nobumori C, Hoenger A, Jiang H, Grovenor CRM, Adeyo O, Esko JD, Goldberg IJ, Reue K, Tontonoz P, Bensadoun A, Beigneux AP, Young SG, Fong LG, Grovenor CR. 2014. The GPIHBP1-LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries. Cell Metabolism 19: 849-860. doi: 10. 1016/j. cmet. 2014. 01. 017.
19. Gårdsvoll H, Werner F, Søndergaard L, Danø K, Ploug M. 2004. Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in drosophila schneider 2 cells after deletion of glycosylation-sites. Protein Expression and Purification 34: 284-295. doi: 10. 1016/j. pep. 2003. 12. 002.
20. Gardsvoll H, Gilquin B, Le Du MH, Mé nè z A, Jørgensen TJ, Ploug M. 2006. Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking. Journal of Biological Chemistry 281: 19260-19272. doi: 10. 1074/jbc. M513583200.
21. Gårdsvoll H, Hansen LV, Jørgensen TJD, Ploug M. 2007. A new tagging system for production of recombinant proteins in drosophila S2 cells using the third domain of the urokinase receptor. Protein Expression and Purification 52: 384-394. doi: 10. 1016/j. pep. 2006. 11. 013.
22. Gardsvoll H, Jacobsen B, Kriegbaum MC, Behrendt N, Engelholm L, Ostergaard S, Ploug M. 2011. Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction. Journal of Biological Chemistry 286: 33544-33556. doi: 10. 1074/jbc. M111. 220087.
23. Gardsvoll H, Kriegbaum MC, Hertz EP, Alpizar-Alpizar W, Ploug M. 2013. The urokinase receptor homolog haldisin is a novel differentiation marker of stratum granulosum in squamous epithelia. Journal of Histochemistry & Cytochemistry 61: 802-813. doi: 10. 1369/0022155413501879.
24. Hansen LV, Gårdsvoll H, Nielsen BS, Lund LR, Danø K, Jensen ON, Ploug M. 2004. Structural analysis and tissue localization of human C4. 4A: a protein homologue of the urokinase receptor. Biochemical Journal 380: 845-857. doi: 10. 1042/bj20031478.
25. Hata A, Ridinger DN, Sutherland S, Emi M, Shuhua Z, Myers RL, Ren K, Cheng T, Inoue I, Wilson DE, Shuhua Z, Myers RL, Ren K. 1993. Binding of lipoprotein lipase to heparin. identification of five critical residues in two distinct segments of the amino-terminal domain. The Journal of Biological Chemistry 268: 8447-8457.
26. Henderson HE, Hassan F, Marais D, Hayden MR. 1996. A new mutation destroying disulphide bridging in the c-terminal domain of lipoprotein lipase. Biochemical and Biophysical Research Communications 227: 189-194. doi: 10. 1006/bbrc. 1996. 1487.
27. Henderson H, Leisegang F, Hassan F, Hayden M, Marais D. 1998. A novel Glu421Lys substitution in the lipoprotein lipase gene in pregnancy-induced hypertriglyceridemic pancreatitis. Clinica Chimica Acta 269: 1-12. doi: 10. 1016/S0009-8981(97)00144-7.
28. Jerabek-Willemsen M, André T, Wanner R, Roth HM, Duhr S, Baaske P, Breitsprecher D. 2014. MicroScale thermophoresis: interaction analysis and beyond. Journal of Molecular Structure 1077: 101-113. doi: 10. 1016/j. molstruc. 2014. 03. 009.
29. Jones DT, Cozzetto D. 2015. DISOPRED3: precise disordered region predictions with annotated protein-binding activity. Bioinformatics 31: 857-863.
30. Jørgensen TJ, Gårdsvoll H, Danø K, Roepstorff P, Ploug M. 2004. Dynamics of urokinase receptor interaction with peptide antagonists studied by amide hydrogen exchange and mass spectrometry. Biochemistry 43: 15044-15057.
31. Karlsson R, Katsamba PS, Nordin H, Pol E, Myszka DG. 2006. Analyzing a kinetic titration series using affinity biosensors. Analytical Biochemistry 349: 136-147. doi: 10. 1016/j. ab. 2005. 09. 034.
32. Kassner U, Salewsky B, Wühle-Demuth M, Szijarto IA, Grenkowitz T, Binner P, Mä rz W, Steinhagen-Thiessen E, Demuth I, Szijarto IA, Grenkowitz T, Binner P, Marz W. 2015. Severe hypertriglyceridemia in a patient heterozygous for a lipoprotein lipase gene allele with two novel missense variants. European Journal of Human Genetics 23: 1259-1261. doi: 10. 1038/ejhg. 2014. 295.
33. Kobayashi Y, Nakajima T, Inoue I. 2002. Molecular modeling of the dimeric structure of human lipoprotein lipase and functional studies of the carboxyl-terminal domain. Eur J Biochem 269: 4701-4710.
34. Korn ED. 1955. Clearing factor, a heparin-activated lipoprotein lipase. i. isolation and characterization of the enzyme from normal rat heart. The Journal of Biological Chemistry 215: 1-14.
35. Kriegbaum MC, Persson M, Haldager L, Alpizar-Alpizar W, Jacobsen B, Gardsvoll H, Kjaer A, Ploug M, Haldager L, Alpízar-Alpízar W, Jacobsen B, Gårdsvoll H, Kjaer A. 2011. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Current Drug Targets 12: 1711-1728. doi: 10. 2174/138945011797635812.
36. Larsson M, Vorrsjo E, Talmud P, Lookene A, Olivecrona G. 2013. Apolipoproteins c-i and c-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. Journal of Biological Chemistry 288: 33997-34008. doi: 10. 1074/jbc. M113. 495366.
37. Lin L, Gardsvoll H, Huai Q, Huang M, Ploug M. 2010. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. Journal of Biological Chemistry 285: 10982-10992. doi: 10. 1074/jbc. M109. 093492.
38. Llinas P, Hé lè ne Le Du M, Gårdsvoll H, Danø K, Ploug M, Gilquin B, Stura EA, Mé nez A. 2005. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. The EMBO Journal 24: 1655-1663. doi: 10. 1038/sj. emboj. 7600635.
39. Lookene A, Chevreuil O, Østergaard P, Olivecrona G. 1996. Interaction of lipoprotein lipase with heparin fragments and with heparan sulfate: stoichiometry, stabilization, and kinetics. Biochemistry 35: 12155-12163. doi: 10. 1021/bi960008e.
40. Mertens HDT, Kjaergaard M, Mysling S, Gårdsvoll H, Jørgensen TJD, Svergun DI, Ploug M. 2012. A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR). Journal of Biological Chemistry 287: 34304-34315. doi: 10. 1074/jbc. M112. 398404.
41. Olivecrona G, Ehrenborg E, Semb H, Makoveichuk E, Lindberg A, Hayden MR, Gin P, Davies BSJ, Weinstein MM, Fong LG, Beigneux AP, Young SG, Olivecrona T, Hernell O. 2010. Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. The Journal of Lipid Research 51: 1535-1545. doi: 10. 1194/jlr. M002717.
42. Osborne JC, Bengtsson-Olivecrona G, Lee NS, Olivecrona T. 1985. Studies on inactivation of lipoprotein lipase: role of the dimer to monomer dissociation. Biochemistry 24: 5606-5611. doi: 10. 1021/bi00341a048.
43. Peng L, Rasmussen MI, Chailyan A, Houen G, Højrup P. 2014. Probing the structure of human protein disulfide isomerase by chemical cross-linking combined with mass spectrometry. Journal of Proteomics 108: 1-16. doi: 10. 1016/j. jprot. 2014. 04. 037.
44. Plengpanich W, Young SG, Khovidhunkit W, Bensadoun A, Karnman H, Ploug M, Gårdsvoll H, Leung CS, Adeyo O, Larsson M, Muanpetch S, Charoen S, Fong LG, Niramitmahapanya S, Beigneux AP, Khovidhunkit W, Bensadoun A, Karnman H, Ploug M, Gårdsvoll H. 2014. Multimerization of glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (gPIHBP1) and familial chylomicronemia from a serine-to-cysteine substitution in GPIHBP1 Ly6 domain. Journal of Biological Chemistry 289: 19491-19499. doi: 10. 1074/jbc. M114. 558528.
45. Ploug M. 2003. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Current Pharmaceutical Design 9: 1499-1528. doi: 10. 2174/1381612033454630.
46. Previato L, Guardamagna O, Dugi KA, Ronan R, Talley GD, Santamarina-Fojo S, Brewer HB. 1994. A novel missense mutation in the c-terminal domain of lipoprotein lipase (glu410->val) leads to enzyme inactivation and familial chylomicronemia. Journal of Lipid Research 35: 1552-1560.
47. Reimund M, Larsson M, Kovrov O, Kasvandik S, Olivecrona G, Lookene A. 2015. Evidence for two distinct binding sites for lipoprotein lipase on glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (gPIHBP1). Journal of Biological Chemistry 290: 13919-13934. doi: 10. 1074/jbc. M114. 634626.
48. Rios JJ, Shastry S, Jasso J, Hauser N, Garg A, Bensadoun A, Cohen JC, Hobbs HH. 2012. Deletion of GPIHBP1 causing severe chylomicronemia. Journal of Inherited Metabolic Disease 35: 531-540. doi: 10. 1007/s10545-011-9406-5.
49. Sali A, Potterton L, Yuan F, van Vlijmen H, Karplus M. 1995. Evaluation of comparative protein modeling by MODELLER. Proteins 23: 318-326. doi: 10. 1002/prot. 340230306.
50. Shevchenko A, Wilm M, Vorm O, Mann M. 1996. Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Analytical Chemistry 68: 850-858. doi: 10. 1021/ac950914h.
51. Soding J. 2005. Protein homology detection by HMM-HMM comparison. Bioinformatics 21: 951-960. doi: 10. 1093/bioinformatics/bti125.
52. Sukonina V, Lookene A, Olivecrona T, Olivecrona G. 2006. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proceedings of the National Academy of Sciences of the United States of America 103: 17450-17455. doi: 10. 1073/pnas. 0604026103.
53. Surendran RP, Visser ME, Heemelaar S, Wang J, Peter J, Defesche JC, Kuivenhoven JA, Hosseini M, Pé terfy M, Kastelein JJP, Johansen CT, Hegele RA, Stroes ESG, Dallinga-Thie GM. 2012. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. Journal of Internal Medicine 272: 185-196. doi: 10. 1111/j. 1365-2796. 2012. 02516. x.
54. Uversky VN. 2012. Size-exclusion chromatography in structural analysis of intrinsically disordered proteins. Methods Mol Biol 896: 179-194. doi: 10. 1007/978-1-4614-3704-8_11.
55. Voss CV, Davies BS, Tat S, Gin P, Fong LG, Pelletier C, Mottler CD. 2011. Mutations in lipoprotein lipase that block binding to the endothelial cell transporter GPIHBP1. Proc Natl Acad Sci U S A 108: 7980-7984.
56. Xu X, Gårdsvoll H, Yuan C, Lin L, Ploug M, Huang M. 2012. Crystal structure of the urokinase receptor in a ligand-free form. J Mol Biol 416: 629-641.
57. Young SG, Zechner R. 2013. Biochemistry and pathophysiology of intravascular and intracellular lipolysis. Genes Dev 27: 459-484.
58. Zhao B, Gandhi S, Yuan C, Luo Z, Li R, Gårdsvoll H, de Lorenzi V. 2015. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation. J Mol Biol 427: 1389-1403.